Form D · Biotechnology
Exin Therapeutics, Inc.
San Francisco, CA · CIK 0002109179
Offering snapshot reported Feb 10, 2026 · SEC filing
- Reported sold
- $2.16M Offering amount: $2.16M
- Investors reported
- 28 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 18, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 10, 2026 | Initial | $2,162,300 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-573167
Source: Form D, filed Feb 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ivan Alex Priela Lazarte | Director, Executive |
| Gabriel Ocana Santero | Director, Executive |
| Marko Tvrdic | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2261 Market Street Ste 22614
San Francisco, CA, 94114
San Francisco, CA, 94114